| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Isotope-labeled compound; the parent compound Danofloxacin targets bacterial DNA gyrase (topoisomerase II) and topoisomerase IV.
|
|---|---|
| ln Vitro |
As a deuterated internal standard, Danofloxacin-d3-1 itself does not exhibit antibacterial activity in vitro. The parent compound Danofloxacin shows potent in vitro activity against a broad spectrum of Gram-negative and Gram-positive bacteria, including Escherichia coli, Salmonella, Pasteurella multocida, and Mycoplasma species, with minimum inhibitory concentration (MIC) values typically in the range of 0.015–2 μg/mL.
|
| ln Vivo |
As a deuterated internal standard, Danofloxacin-d3-1 itself does not exhibit antibacterial activity in vivo. The parent compound Danofloxacin demonstrates excellent in vivo efficacy in veterinary species, with good tissue penetration and broad-spectrum activity against respiratory and enteric pathogens in poultry, swine, and cattle.
|
| Enzyme Assay |
Non-cell-based assay protocols for isotope-labeled compounds typically involve liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. A typical workflow includes sample preparation (protein precipitation or solid-phase extraction), chromatographic separation on a C18 column with a mobile phase of acetonitrile and 0.1% formic acid, and MS/MS detection in multiple reaction monitoring (MRM) mode. The deuterated compound serves as an internal standard to correct for matrix effects and extraction recovery.
|
| Cell Assay |
Cell-based assays are not applicable to Danofloxacin-d3-1 as it is an analytical standard. However, the parent compound Danofloxacin is evaluated in cell-based antibacterial susceptibility testing following CLSI or EUCAST guidelines, using broth microdilution or agar dilution methods to determine MIC values against bacterial strains in appropriate growth media.
|
| Animal Protocol |
In vivo animal studies for Danofloxacin-d3-1 are not conducted as it is an analytical standard. The parent compound Danofloxacin is administered orally or via injection in pharmacokinetic studies in poultry, swine, and cattle. Typical dosing regimens include 2.5–5 mg/kg body weight, with blood and tissue samples collected at predetermined time points for drug concentration analysis.
|
| ADME/Pharmacokinetics |
As a deuterated internal standard, Danofloxacin-d3-1 has no pharmacokinetic properties of its own. The parent compound Danofloxacin exhibits favorable PK properties in veterinary species: oral bioavailability of 60–80%, volume of distribution of 2–4 L/kg, plasma protein binding of 30–40%, elimination half-life of 3–8 hours in poultry and 5–10 hours in mammals, and renal excretion as the primary elimination route.
|
| Toxicity/Toxicokinetics |
As a deuterated internal standard for research use, Danofloxacin-d3-1 is not intended for human or veterinary therapeutic use and therefore has no established toxicological profile. The parent compound Danofloxacin is well-tolerated in target animal species at recommended doses, with a safety margin of approximately 3–5 times the therapeutic dose.
|
| References |
|
| Additional Infomation |
Deuterium-labeled compounds such as Danofloxacin-d3-1 are essential tools in bioanalytical chemistry for accurate drug quantification. The deuterium substitution provides a mass shift of 3 Da from the parent compound, enabling simultaneous detection without chromatographic interference. These labeled standards are critical for regulatory bioequivalence studies and pharmacokinetic research in veterinary drug development.
|
| Molecular Formula |
C19H17D3FN3O3
|
|---|---|
| Molecular Weight |
360.40
|
| Exact Mass |
357.148
|
| CAS # |
1217683-55-0
|
| PubChem CID |
14650736
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
337-339°C
|
| LogP |
-0.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
679
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1=CC2C(C(C(=O)O)=CN(C=2C=C1N1C[C@@H]2C[C@H]1CN2C([2H])([2H])[2H])C1CC1)=O
|
| InChi Key |
QMLVECGLEOSESV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)
|
| Chemical Name |
1-cyclopropyl-6-fluoro-7-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-4-oxoquinoline-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7747 mL | 13.8735 mL | 27.7469 mL | |
| 5 mM | 0.5549 mL | 2.7747 mL | 5.5494 mL | |
| 10 mM | 0.2775 mL | 1.3873 mL | 2.7747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
